Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.6952W HIGH $13.90
Volume
4.00 M
Value Traded
55.56 M
Short % Float
7.55%
Days to Cover
8.5
+0.36%Week
+1.02%1 Month
+1.46%3 Month
+3.58%6 Month
-65.12%5 Year
-56.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.65 B
EPS (TTM)
0.81
P/E Ratio
17.14
Ent. Value
10.75 B
Total Shares
262.52 M
Float Shares
260.94 M
Insiders
0.64%
Institutions
84.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
OGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Organon & Co.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Organon & Co.
134Total events
5Upcoming
50Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Subgroup AnalysisVTAMAApprovedClinical Data
Consistent EASI75, vIGA-AD and PP-NRS responses across patient subgroups in pooled ADORING 1/2 data
atopic dermatitissource ↗
◆Poster PresentationHADLIMAApprovedPresentation
Poster presentation of real-world evidence on VA switch from HUMIRA to HADLIMA
rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitissource ↗
▲RWE DataHADLIMAApprovedClinical Data
Real-world evidence shows 1.3% switchback rate and $132M VA savings after switch to HADLIMA
rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitissource ↗
▲Interim Efficacy DataMiudellaApprovedClinical Data
Positive interim Phase 3 results for MIUDELLA through 6 years of use
◆Poster PresentationVTAMAApprovedPresentation
Real-world analysis of VTAMA cream in AD to be presented at 2026 Fall Clinical Dermatology Conference
atopic dermatitissource ↗
▲FDA Filing AcceptedMiudellaApprovedRegulatory Filing
FDA accepts for review Sebela's sNDA for MIUDELLA to extend duration of use to 6 years
prevention of pregnancysource ↗
▲REMS ModifiedMiudellaApprovedPost-Market
MIUDELLA REMS program opened for enrollment
prevention of pregnancysource ↗
▲Poster PresentationVTAMAApprovedPresentation
Poster of pooled ADORING 1/2 age-stratified data presented at 2026 SPD Annual Meeting
atopic dermatitissource ↗
▲Subgroup AnalysisVTAMAApprovedClinical Data
Pooled Phase 3 vIGA-AD and EASI75 results broken out by pediatric and adult age subsets
atopic dermatitissource ↗
▲Product LaunchBildyosApprovedPost-Market
Launch of BILDYOS (denosumab injection) in Canada
osteoporosis (Prolia biosimilar)source ↗
▲Product LaunchTUZEMTYPost-Market
Launch of TUZEMTY (denosumab injection) in Canada
bone metastases (Xgeva biosimilar)source ↗
▲Partnership / LicenseMiudellaApprovedCorporate
Organon completes license agreement for MIUDELLA hormone-free IUD
▲Partnership / LicensePYZCHIVACorporate
Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA in Canada
▲Label ExpansionTofidenceApprovedFDA Decision
FDA approval expanding indications for TOFIDENCE in CRS and pediatric COVID-19
Cytokine Release Syndrome (CRS) and Pediatric COVID-19source ↗
▲Partnership / LicenseMiudellaApprovedCorporate
Organon completed agreement to exclusively license global rights to Sebela's MIUDELLA
prevention of pregnancysource ↗
◆Quarterly UpdateCorporate
Organon to report first quarter 2026 financial results and host conference call
▲EU ApprovalPOHERDYApprovedEx-US Regulatory
European Commission grants marketing authorization for POHERDY (pertuzumab) as first biosimilar of PERJETA in Europe
HER2-positive breast cancersource ↗
▲EU ApprovalPOHERDYApprovedEx-US Regulatory
EC granted marketing authorization for POHERDY (pertuzumab) as first biosimilar to PERJETA in Europe
HER2-positive breast cancersource ↗
◆AcquisitionCorporate
Sun Pharma announces definitive agreement to acquire Organon for $14.00 per share
◆Oral PresentationVTAMAApprovedPresentation
Oral presentation of pooled post-hoc sub-analysis from ADORING 1 and 2 at AAD 2026
atopic dermatitissource ↗
▲Poster PresentationVTAMAApprovedPresentation
Poster presentation of sub-analysis of pooled Phase 3 data on sleep subdomains in pediatric patients at AAAAI 2026
atopic dermatitissource ↗
▲Partnership / LicenseMiudellaApprovedCorporate
Organon licenses global rights to MIUDELLA from Sebela Pharmaceuticals
prevention of pregnancysource ↗
▲Product LaunchNEXPLANONApprovedPost-Market
NEXPLANON REMS program planned availability start
prevention of pregnancysource ↗
◆Quarterly UpdateCorporate
Q4 and Full Year 2025 Financial Results Release and Conference Call
▲Supplemental ApprovalNEXPLANONApprovedFDA Decision
FDA approval of sNDA extending NEXPLANON duration of use to up to five years
prevention of pregnancysource ↗
◆REMS ModifiedNEXPLANONApprovedPost-Market
New REMS program for NEXPLANON to mitigate insertion/removal complications
prevention of pregnancysource ↗
▲Full ResultsNEXPLANONApprovedClinical Data
Extended-use trial results: no pregnancies in years 4-5, Pearl Index 0.0
prevention of pregnancysource ↗
▲FDA ApprovalBilprevdaApprovedFDA Decision
FDA approved Bilprevda (denosumab-nxxp) in September 2025
denosumab biosimilarsource ↗
▲FDA ApprovalBildyosApprovedFDA Decision
FDA approved Bildyos (denosumab-nxxp) in September 2025
denosumab biosimilarsource ↗
▲Interchangeability DesignationHADLIMAApprovedIP / Competition
FDA grants interchangeability designation to HADLIMA high- and low-concentration autoinjectors and high-concentration prefilled syringe
rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitissource ↗
Past FDA Catalysts and PDUFA Decisions
How OGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-28 | VTAMA (tapinarof) cream, 1% | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 47%
Small Cap(rank 324 of 689)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Nexplanon/Implanon NXT | |||
| Zetia | |||
| Atozet | |||
| Hadlima | |||
| Other Non-Opiod Pain, Bone and Dermatology | |||
| Arcoxia | |||
| Nasonex | |||
| Renflexis | |||
| Follistim AQ | |||
| Emgality | |||
| Cozaar/Hyzaar | |||
| Singulair |
Top 12 of 27 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tapinarof Small MoleculesMarketedNCT07265479 | Atopic Dermatitis | Approved | ACTIVE NOT_RECRUITING | 1,764 | Aug 1, 2027 | ||||||
| OG-6219 Small MoleculesCompletedNCT05560646 | Endometriosis | Phase 2 | COMPLETED | 354 | May 28, 2025 | ||||||
| Mometasone furoate Small MoleculesMarketedNCT00635882 | Asthma | Approved | COMPLETED | 3,225 | Jun 1, 2009 | ||||||
| MK0906, finasteride/ Duration of Treatment: 48 Weeks Small MoleculesMarketedNCT00396175 | Androgenetic Alopecia | Approved | COMPLETED | 355 | - | ||||||
| Desloratadine Small MoleculesMarketedNCT00757562 | Chronic Idiopathic Urticaria | Approved | COMPLETED | 97 | Oct 1, 2003 | ||||||
| Desloratadine Small MoleculesNot countedNCT01916980 | Eczema | Phase 3 | COMPLETED | 94 | Mar 22, 2014 | ||||||
| Desloratadine Small MoleculesNot countedNCT00817076 | Dermatitis, Atopic | Phase 3 | COMPLETED | 40 | Jul 1, 2003 | ||||||
| alendronate Small MoleculesMarketedNCT00480662 | Paget's Disease of Bone | Approved | COMPLETED | 60 | Oct 1, 2002 | ||||||
| etoricoxib Small MoleculesNot countedNCT01554163 | Osteoarthritis of the Knee | Phase 3 | COMPLETED | 239 | Mar 1, 2013 | ||||||
| etoricoxib Small MoleculesNot countedNCT01208207 | Spondylitis, Ankylosing | Phase 3 | COMPLETED | 1,015 | Nov 12, 2014 | ||||||
| etoricoxib Small MoleculesNot countedNCT00264147 | Rheumatoid Arthritis | Phase 3 | COMPLETED | 2,165 | Mar 1, 2008 | ||||||
| Tapinarof Small MoleculesMarketedNCT04042103 | Plaque Psoriasis | Approved | COMPLETED | 1,867 | Jan 9, 2020 | ||||||
| Desloratadine Small MoleculesMarketedNCT01916967 | Urticaria | Approved | COMPLETED | 521 | Mar 13, 2014 | ||||||
| Mometasone furoate Small MoleculesNot countedNCT00599027 | Allergic Rhinitis | Phase 3 | COMPLETED | 1,763 | May 1, 2009 | ||||||
| Mometasone furoate Small MoleculesNot countedNCT00383721 | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | COMPLETED | 2,251 | Jul 1, 2010 | ||||||
| Mometasone Small MoleculesNot countedNCT00783224 | Perennial Allergic Rhinitis | Phase 3 | COMPLETED | 351 | Dec 1, 2005 | ||||||
| Desloratadine Small MoleculesMarketedNCT01918033 | Perennial Allergic Rhinitis | Approved | COMPLETED | 608 | Jan 26, 2014 | ||||||
| Desloratadine Small MoleculesMarketedNCT00794378 | Allergic Rhinitis | Approved | COMPLETED | 487 | Nov 1, 2004 | ||||||
| Montelukast Granules Small MoleculesMarketedNCT01852812 | Perennial Allergic Rhinitis | Approved | COMPLETED | 87 | Dec 24, 2013 | ||||||
| 5-mg Desloratadine Small MoleculesMarketedNCT00405964 | Allergic Rhinitis | Approved | COMPLETED | 716 | Apr 1, 2008 | ||||||
| 5-mg Desloratadine Small MoleculesMarketedNCT00406783 | Rhinitis, Allergic, Seasonal | Approved | COMPLETED | 547 | Nov 1, 2007 | ||||||
| loratadine; montelukast Small MoleculesMarketedNCT00319995 | Rhinitis, Allergic, Seasonal | Approved | COMPLETED | 1,095 | Jun 28, 2006 | ||||||
| Desloratadine Small MoleculesMarketedNCT02320396 | Seasonal Allergic Rhinitis | Approved | COMPLETED | 503 | Apr 27, 2015 | ||||||
| Mometasone furoate Small MoleculesNot countedNCT01386125 | Nasal Polyps | Phase 3 | COMPLETED | 1,037 | Feb 1, 2013 | ||||||
| Mometasone furoate Small MoleculesNot countedNCT03855189 | Seasonal Allergic Rhinitis | Phase 3 | COMPLETED | 2,393 | Oct 22, 1993 |
Clinical Trial Results
Readouts, endpoints and source filings for every OGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VTAMA | atopic dermatitis | Phase 3 | 2026-11-12 | EASI75: <10% BSA involvement 57.8% vs. 32.2%, ≥10% BSA involvement 64.4% vs. 23.2%, 0 · 5 years disease duration 70.0% vs. 31.8%, ≥6 years disease duration 58.8% vs. 21.7%, prior treatment 64.3% vs. 3.8%, no prior treatment 62.4% vs. 28.4%; v IGA AD: <10% BSA involvement 53.9% vs. 22.0%, ≥10% BSA involvement 46.0% vs. 15.2%, 0 · 5 years disease duration 53.2% vs. 17.6%, ≥6 years disease duration 45.3% vs. 16.7%, prior treatment 45.7% vs. 7.7%, no prior treatment 48.4% vs. 18.3%; PP NRS: <10% BSA involvement 61.3% vs. 26.1%, ≥10% BSA involvement 58.6% vs. 35.8%, 0 · 5 years disease duration 64.9% vs. 30.6%, ≥6 years disease duration 56.1% vs. 35.2%, prior treatment 55.0% vs. 20.8%, no prior treatment 60.0% vs. 35.3%Read More | Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAIRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Holzbaur LynetteOfficer (SVP and Corporate Controller) | Option | 2,418 4,590 held | $0.00 | 11/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 1.2 % (-20 %) | 6.20 M | 640.00 K | 19.63% ( 105.00 K) |
Ownership Trends
OGN Short Interest
Shares sold short, counted twice a month.
7.55%
Short % of Float
of tradable shares sold short
19.7M
Shares Sold Short
+4.7% vs prior count
8.5 High
Days to Cover
trading days of normal volume to buy every short share back
2.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OGN ranks across every disease it competes in
Competitive Position is a premium feature
See how OGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOGN News
OGNOrganon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
Organon presented new pooled data from Phase 3 trials of VTAMA cream at the ACAAI meeting. The analysis showed consistent efficacy in treating moderate to severe atopic dermatitis across various patient subgroups. Results indicated significant improvements in disease severity and itch from Week 1 through Week 8. VTAMA cream is well tolerated and offers a non-steroidal treatment option.
Read more →OGNNew Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
Organon presented new evidence at the ACR Annual Meeting showing a successful transition of over 16,000 veterans from HUMIRA to HADLIMA. The switch resulted in a low switchback rate of 1.3% and significant cost savings of $132 million for the Veterans Affairs Healthcare System. Average pharmacy costs decreased by $8,100 per patient in the first year.
Read more →OGNOrganon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Organon announced a new analysis of VTAMA cream efficacy in atopic dermatitis, to be presented at the 2026 ACAAI Annual Scientific Meeting. The analysis evaluates data from Phase 3 trials, focusing on diverse patient subgroups. The presentation is scheduled for November 14, 2026, in Phoenix, Arizona.
Read more →OGNOrganon Announces Quarterly Dividend
Organon announced a quarterly dividend of $0.02 per share, payable on December 10, 2026. Stockholders of record as of November 9, 2026, will receive this dividend. The company emphasizes its commitment to women's health and expanding access to essential treatments.
Read more →OGNEntera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
Entera Bio Ltd. appointed Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026. Dr. Arjona Ferreira, currently at Organon, brings two decades of experience in clinical development and women's health. His expertise will support Entera's clinical strategy, particularly for its osteoporosis treatment, EB613.
Read more →OGNOrganon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon plans to release its third quarter 2026 financial results through a Form 10-Q filing with the SEC. The company will also provide non-GAAP financial measures in a Form 8-K filing on the same day. Currently, Organon does not expect to incur any milestone expenses for this quarter. The company has suspended its quarterly earnings calls due to a pending acquisition by Sun Pharmaceutical Industries.
Read more →OGNOrganon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Organon announced positive interim results from a Phase 3 study of MIUDELLA, a hormone-free IUD, showing efficacy and safety through 6 years of use. The study evaluated 465 participants, revealing a cumulative Pearl Index of 0.93. No new safety signals were reported, supporting the FDA's review for extended use. The findings will be presented at the 2026 Society of Family Planning Annual Meeting.
Read more →OGNOrganon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Organon is set to present its first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1%, specifically targeting patients with eczema. This presentation will take place at the upcoming Fall Clinical Dermatology Conference, showcasing the company's commitment to advancing treatment options in dermatology.
Read more →OGNOrganon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Organon has announced that the U.S. FDA has accepted for review its supplemental new drug application (sNDA) for MIUDELLA®, a hormone-free intrauterine device (IUD). The application seeks to extend the approved duration of use from 3 years to 6 years. This could provide patients with more options for long-term contraception.
Read more →OGNOrganon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
Organon has initiated the REMS certification process for its hormone-free copper IUD, MIUDELLA, in preparation for its upcoming commercial launch. Healthcare providers, settings, and pharmacies can now begin certification, indicating a proactive approach to ensure safe distribution. This move highlights Organon's commitment to expanding its product offerings in women's health.
Read more →OGNNew Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Organon has presented new analysis from Phase 3 pooled data for its VTAMA (tapinarof) cream, 1%. The data indicates early and consistent improvements in patients with atopic dermatitis across various pediatric age groups and adults. This analysis highlights the potential effectiveness of VTAMA in treating eczema.
Read more →OGNOrganon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon plans to announce its second quarter 2026 financial results through a Form 10-Q filing with the SEC. The report will include certain non-GAAP financial measures along with their reconciliation to GAAP measures. This move reflects the company's commitment to transparency in its financial reporting.
Read more →OGNOrganon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
Organon is set to present a new analysis of VTAMA® (tapinarof) cream, 1% at the upcoming 2026 Society for Pediatric Dermatology Annual Meeting. This presentation highlights the company's ongoing commitment to pediatric dermatology. Details regarding the analysis and its implications for treatment will be shared during the meeting.
Read more →OGNOrganon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
Organon Canada and Henlius have launched BILDYOS® and TUZEMTY®, biosimilars to PROLIA and XGEVA, aimed at expanding access to denosumab treatments. This initiative is expected to enhance treatment options for patients requiring denosumab therapy. The launch reflects a strategic move to provide more affordable alternatives in the market.
Read more →OGNOrganon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon has finalized an agreement to license MIUDELLA®, a hormone-free intrauterine device developed by Sebela Pharmaceuticals. This collaboration aims to enhance Organon's portfolio in women's health. The details regarding the financial terms of the agreement have not been disclosed.
Read more →OGNOrganon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
Organon and Samsung Bioepis have expanded their agreement to commercialize PYZCHIVA®, a biosimilar referencing STELARA® (ustekinumab), in Canada. This collaboration aims to enhance the availability of this treatment in the Canadian market. Further details regarding the terms of the agreement or expected timelines were not disclosed.
Read more →OGNOrganon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Organon has secured FDA approval for TOFIDENCE® (tocilizumab-bavi), expanding its indications to include treatment for Cytokine Release Syndrome (CRS) and pediatric COVID-19. This approval enhances the therapeutic options available for these conditions, particularly benefiting younger patients. The decision reflects the ongoing need for effective treatments in critical health scenarios.
Read more →OGNOrganon to Present New Research on Access and Value at ISPOR 2026
Organon will present new research at ISPOR 2026, focusing on women's health and biosimilars. The data, derived from eight accepted abstracts, emphasizes the importance of health economics in ensuring effective treatment access. Key topics include the budget impact of contraceptive methods and real-world healthcare utilization patterns. The conference will take place from May 17-20, 2026, in Philadelphia.
Read more →OGNOrganon Reports Results for the First Quarter Ended March 31, 2026
Organon reported its Q1 2026 financial results, showing a total revenue of $1.460 billion, down 4% from the previous year. Women's Health revenue saw a significant decline, particularly in Nexplanon sales, which dropped 21% due to decreased physician demand and funding uncertainties. However, the company experienced growth in its biosimilars segment, with a 23% increase in revenue. Net income rose to $146 million, reflecting a 68% increase compared to Q1 2025.
Read more →About Organon & Co.
Headquarters30 HUDSON STREET, JERSEY CITY, NJ, 07302
BIOPHARMAWATCH ELITE
Trade the next OGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime